Last reviewed · How we verify
MN rgp120/HIV-1 and A244 rgp120/HIV-1
MN rgp120/HIV-1 and A244 rgp120/HIV-1 is a HIV vaccine Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for HIV-1 prevention in seronegative adults.
MN rgp120/HIV-1 and A244 rgp120/HIV-1 are recombinant HIV envelope protein vaccines designed to elicit immune responses against the gp120 surface antigen of HIV-1.
MN rgp120/HIV-1 and A244 rgp120/HIV-1 are recombinant HIV envelope protein vaccines designed to elicit immune responses against the gp120 surface antigen of HIV-1. Used for HIV-1 prevention in seronegative adults.
At a glance
| Generic name | MN rgp120/HIV-1 and A244 rgp120/HIV-1 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | HIV vaccine |
| Target | gp120 (HIV-1 envelope glycoprotein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
These vaccines present recombinant gp120 proteins from different HIV-1 strains (MN and A244) to stimulate both humoral and cellular immune responses against the envelope glycoprotein. By targeting gp120, a critical component of HIV's entry mechanism, the vaccines aim to generate neutralizing antibodies and T-cell responses that can prevent or control HIV-1 infection.
Approved indications
- HIV-1 prevention in seronegative adults
Common side effects
- Injection site reactions (pain, erythema, induration)
- Systemic reactions (fever, fatigue, myalgia)
- Headache
Key clinical trials
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults (PHASE1)
- A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers (PHASE2)
- Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand (PHASE3)
- A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MN rgp120/HIV-1 and A244 rgp120/HIV-1 CI brief — competitive landscape report
- MN rgp120/HIV-1 and A244 rgp120/HIV-1 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about MN rgp120/HIV-1 and A244 rgp120/HIV-1
What is MN rgp120/HIV-1 and A244 rgp120/HIV-1?
How does MN rgp120/HIV-1 and A244 rgp120/HIV-1 work?
What is MN rgp120/HIV-1 and A244 rgp120/HIV-1 used for?
Who makes MN rgp120/HIV-1 and A244 rgp120/HIV-1?
What drug class is MN rgp120/HIV-1 and A244 rgp120/HIV-1 in?
What development phase is MN rgp120/HIV-1 and A244 rgp120/HIV-1 in?
What are the side effects of MN rgp120/HIV-1 and A244 rgp120/HIV-1?
What does MN rgp120/HIV-1 and A244 rgp120/HIV-1 target?
Related
- Drug class: All HIV vaccine drugs
- Target: All drugs targeting gp120 (HIV-1 envelope glycoprotein)
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for HIV-1 prevention in seronegative adults